Form 8-K - Current report:
SEC Accession No. 0001193125-25-144204
Filing Date
2025-06-23
Accepted
2025-06-23 08:15:20
Documents
14
Period of Report
2025-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d915163d8k.htm   iXBRL 8-K 29560
2 EX-99.1 d915163dex991.htm EX-99.1 13863
6 GRAPHIC g915163g0622232817148.jpg GRAPHIC 5384
  Complete submission text file 0001193125-25-144204.txt   176516

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cadl-20250620.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20250620_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20250620_pre.xml EX-101.PRE 11709
16 EXTRACTED XBRL INSTANCE DOCUMENT d915163d8k_htm.xml XML 3765
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 251063018
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)